Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021.

ABSTRACT: The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of anti-FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII products. Bypassing agents to control bleeding episodes are recommended for these patients, but their efficacy is difficult to predict and monitor. FVIII products derived from porcine plasma had an important role in the treatment of hemophilia A for 50 years, from 1954 to 2004. Indeed, porcine FVIII could achieve hemostasis in patients in whom human FVIII products were ineffective. A recombinant porcine FVIII product is now available. This highly purified protein has the same biochemical and hemostatic properties, but much lower risks of infection and toxicity compared with plasma-derived porcine FVIII. The pro

SUBMITTER: Dargaud Y 

PROVIDER: S-EPMC8606027 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature